TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells M Bartucci, R Dattilo, C Moriconi, A Pagliuca, M Mottolese, G Federici, ... Oncogene 34 (6), 681-690, 2015 | 392 | 2015 |
Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer M Musumeci, V Coppola, A Addario, M Patrizii, M Maugeri-Sacca, ... Oncogene 30 (41), 4231-4242, 2011 | 286 | 2011 |
Cancer stem cells and chemosensitivity M Maugeri-Saccà, P Vigneri, R De Maria Clinical Cancer Research 17 (15), 4942-4947, 2011 | 249 | 2011 |
DNA damage repair pathways in cancer stem cells M Maugeri-Sacca, M Bartucci, R De Maria Molecular cancer therapeutics 11 (8), 1627-1636, 2012 | 214 | 2012 |
Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy M Bartucci, S Svensson, P Romania, R Dattilo, M Patrizii, M Signore, ... Cell Death & Differentiation 19 (5), 768-778, 2012 | 214 | 2012 |
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden D Marinelli, M Mazzotta, S Scalera, I Terrenato, F Sperati, L D'Ambrosio, ... Annals of Oncology 31 (12), 1746-1754, 2020 | 188 | 2020 |
The Hippo pathway in normal development and cancer M Maugeri-Saccà, R De Maria Pharmacology & therapeutics 186, 60-72, 2018 | 168 | 2018 |
Triple positive breast cancer: a distinct subtype? P Vici, L Pizzuti, C Natoli, T Gamucci, L Di Lauro, M Barba, D Sergi, ... Cancer treatment reviews 41 (2), 69-76, 2015 | 158 | 2015 |
Metabolic features of cancer stem cells: the emerging role of lipid metabolism R Mancini, A Noto, ME Pisanu, C De Vitis, M Maugeri-Saccà, G Ciliberto Oncogene 37 (18), 2367-2378, 2018 | 131 | 2018 |
BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial–mesenchymal transition V Coppola, M Musumeci, M Patrizii, A Cannistraci, A Addario, ... Oncogene 32 (14), 1843-1853, 2013 | 126 | 2013 |
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives E Krasniqi, G Barchiesi, L Pizzuti, M Mazzotta, A Venuti, M Maugeri-Saccà, ... Journal of hematology & oncology 12, 1-26, 2019 | 125 | 2019 |
Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies P Vici, L Pizzuti, L Mariani, G Zampa, D Santini, L Di Lauro, T Gamucci, ... Expert review of vaccines 15 (10), 1327-1336, 2016 | 110 | 2016 |
Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: a systematic review and meta-analysis of phase III randomized clinical … A Grassadonia, I Sperduti, P Vici, L Iezzi, D Brocco, T Gamucci, L Pizzuti, ... Journal of Clinical Medicine 7 (12), 542, 2018 | 103 | 2018 |
The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications M Maugeri-Saccà, M Barba, L Pizzuti, P Vici, L Di Lauro, R Dattilo, I Vitale, ... Expert reviews in molecular medicine 17, e14, 2015 | 95 | 2015 |
SCD1, autophagy and cancer: implications for therapy F Ascenzi, C De Vitis, M Maugeri-Saccà, C Napoli, G Ciliberto, R Mancini Journal of Experimental & Clinical Cancer Research 40 (1), 265, 2021 | 94 | 2021 |
CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells G Manic, M Signore, A Sistigu, G Russo, F Corradi, S Siteni, M Musella, ... Gut 67 (5), 903-917, 2018 | 94 | 2018 |
Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trials F Sperati, P Vici, M Maugeri-Saccà, S Stranges, N Santesso, L Mariani, ... PloS one 8 (7), e69269, 2013 | 80 | 2013 |
Emerging biological treatments for uterine cervical carcinoma P Vici, L Mariani, L Pizzuti, D Sergi, L Di Lauro, E Vizza, F Tomao, ... Journal of Cancer 5 (2), 86, 2014 | 77 | 2014 |
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma ME Pisanu, M Maugeri-Saccà, L Fattore, S Bruschini, C De Vitis, E Tabbì, ... Journal of Experimental & Clinical Cancer Research 37, 1-17, 2018 | 76 | 2018 |
Mutations in the KEAP1-NFE2L2 pathway define a molecular subset of rapidly progressing lung adenocarcinoma F Goeman, F De Nicola, S Scalera, F Sperati, E Gallo, L Ciuffreda, ... Journal of Thoracic Oncology 14 (11), 1924-1934, 2019 | 73 | 2019 |